Ritter Pharmaceuticals has partnered with the University of British Columbia (UBC)’s Michael Smith Laboratories in Canada to explore development of microbiome and RP-G28 in environmental enteropathy (EE).
As part of the collaboration, Ritter is providing its lead compound RP-G28 for use in the study and UBC microbiologist Dr B Brett Finlay will explore the microbiome’s role in EE.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The latest pre-clinical research has been designed to build upon Dr Finlay’s studies that were previously published, demonstrating the gut microbiome’s role in contributing to the causes of EE.
Ritter Pharmaceuticals co-founder and president Andrew Ritter said: “We are pleased to be collaborating with Dr Finlay and his team to better understand therapeutic interventions that may reverse signs of environmental enteropathy, a significant worldwide health issue.
“We’re excited to apply our clinical knowledge of RP-G28 in a way that has significant possibilities to produce substantial social benefits in developing countries.”
At present, RP-G28 is in a Phase IIb/3 study in humans for the treatment of lactose intolerance and has demonstrated beneficial changes to the gut microbiome in earlier studies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDr Finlay said: “We are pleased to be working with Ritter Pharmaceuticals to explore potential treatments and therapies to environmental enteropathy that affects so many of the world’s children.
“Testing RP-G28 in the relevant model will greatly facilitate preclinical testing of this compound for affecting the outcome of EE.”
Ritter’s RP-G28 has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects people worldwide.
